The case for licensing biopharma patents after loss of exclusivity

By Paul Fehlner

Greater licensing of their secondary patents would not only generate additional income for many pharma companies but would also enable the industry to serve patients better and avoid political controversy

Most pharmaceutical products depend on a patent that covers the active pharmaceutical ingredient to ensure exclusivity in the market. Often other patents also cover aspects of the drug product discovered during the development process – these are known as ‘development patents’ or sometimes ‘secondary patents’.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

Very impressed. Clear, usable insights into the business of IP, and particularly awareness of new strategic IP concepts and tools. I also find it effective for helping frame IP issues with clients and benchmarking to IAM best practice examples. Compares well with the LES journal, and both together cover a broad and thorough toolkit for any IP-centric businessperson.

David Todd
President/IP strategy consultant
Isentient Technologies Corp


Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?


Register for more free content

  • Read more IAM blogs and articles
  • Receive the editor's weekly review by email
Register now  
Issue 90